Media headlines about Incyte (NASDAQ:INCY) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Incyte earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.9245575573833 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Incyte (INCY) Lifted to Sell at BidaskClub (americanbankingnews.com)
- Incyte Co. (INCY) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Merck to Pay $300M Upfront to Co-Develop Eisai’s Cancer Drug – Nasdaq (nasdaq.com)
- Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights – GlobeNewswire (press release) (globenewswire.com)
- The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte (finance.yahoo.com)
Shares of Incyte (INCY) traded up $0.22 during mid-day trading on Monday, hitting $94.45. 1,430,000 shares of the company traded hands, compared to its average volume of 1,680,000. The company has a market cap of $19,930.00, a P/E ratio of -60.54 and a beta of 0.64. The company has a quick ratio of 3.99, a current ratio of 4.01 and a debt-to-equity ratio of 0.01. Incyte has a 1-year low of $80.85 and a 1-year high of $153.15.
A number of research analysts have recently commented on the stock. BMO Capital Markets reissued a “buy” rating and issued a $172.00 price objective on shares of Incyte in a research report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Incyte from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada decreased their price objective on shares of Incyte from $136.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 21st. Raymond James Financial reissued a “buy” rating on shares of Incyte in a research report on Tuesday, December 12th. Finally, ValuEngine downgraded shares of Incyte from a “hold” rating to a “sell” rating in a research report on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $142.83.
In other Incyte news, EVP Reid M. Huber sold 1,958 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.55, for a total value of $167,506.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David W. Gryska sold 6,760 shares of the business’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the completion of the sale, the insider now directly owns 20,752 shares of the company’s stock, valued at approximately $2,051,750.24. The disclosure for this sale can be found here. Insiders sold a total of 15,670 shares of company stock valued at $1,489,181 in the last three months. Insiders own 17.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3258255/incyte-incy-given-daily-media-sentiment-score-of-0-18.html.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.